Hu3S193 in Treating Women With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

DISEASE CHARACTERISTICS: * Histologically confirmed ovarian epithelial, fallopian tube, or primary peritoneal carcinoma * Progressive disease * Disease must express Lewis-Y antigen documented by immunohistochemistry in archived or fresh primary or metastatic tumor biopsies * Measurable disease, including at least one measurable lesion, according to RECIST criteria or CA-125 (Cancer Antigen-125) \> 2 times upper normal limit * Pleural effusion, ascites, bone metastases, and lesions located in previously irradiated areas are not considered measurable * Disease must be considered platinum-refractory or resistant, meeting any of the following criteria: * Platinum-refractory defined as progression during the initial platinum-based chemotherapy regimen or failure to achieve a complete response (e.g., stable disease or partial response) with evidence of progressive disease (by physical examination, radiological exams, or CA-125) during the initial platinum-based chemotherapy * Platinum-resistant defined as recurrence within six months of completion of the initial platinum-based regimen (primary platinum-resistance) or recurrence after six months of completion of the initial platinum-based regimen (still considered platinum-sensitive, but incurable by any approach, that will progress to a secondary platinum-resistance scenario) and failure to ≥ 1 re-induction with a platinum-based regimen (secondary platinum-resistance) * No high tumor burden, as assessed by the investigator * No rapidly progressing disease, as assessed by clinical evaluation * No known CNS (Central Nervous System) involvement by tumor PATIENT CHARACTERISTICS: Inclusion criteria: * Karnofsky performance status \> 70% * Life expectancy ≥ 12 weeks * ANC (absolute neutrophil count) ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Serum bilirubin ≤ 2.0 mg/dL * AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ≤ 2.5 times upper limit of normal (ULN) (≤ 5 times ULN if with liver metastases) * Creatinine ≤ 2.0 mg/dL * Prothrombin time \< 1.3 times control * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception Exclusion criteria: * NYHA (New York Heart Association) class III or IV heart disease * Clinically significant arrhythmias by ECG * Myocardial infarction within the past 6 months * Any other serious illness, including any of the following: * Severe ascites * Severe active infections requiring antibiotics * Bleeding disorders * Chronic inflammatory bowel disease * Diseases that might interfere with the collection of accurate results from this study * Positive for human anti-human antibodies * Prior history of tumor (excluding adequately treated nonmelanoma skin cancer or carcinoma in situ of the uterine cervix) * Uncontrolled hypercalcemia (i.e., \> 11.5 mg/dL) PRIOR CONCURRENT THERAPY: * See Disease Characteristics * Recovered from the toxic effects of any prior therapy * No concurrent systemic steroids or immunosuppressant agents * No more than 1 prior non-platinum-containing regimen for the treatment of platinum-resistant/refractory disease * Patients who receive 2 or more different non-platinum-containing chemotherapy regimens for platinum-resistant/refractory disease are not eligible * More than 4 weeks since prior and no other concurrent chemotherapy, radiotherapy, radiopharmaceuticals (e.g., \^32P), biological therapy, anti-estrogen therapy (including tamoxifen), immunotherapy, or surgery * More than12 weeks since prior investigational agent * No prior treatment with a murine or humanized antibody and/or antibody fragment